ALK and non-small cell lung carcinoma: The ICER obtained (both base case and sensitive analysis) confirms that determining ALK rearrangement in patients with advanced NSCLC is a cost-effective strategy, since it is below the cost-effectiveness thresholds usually considered in Spain [50, 51].